PT - JOURNAL ARTICLE AU - Hong, Mun-Gwan AU - Khemiri, Lotfi AU - Guterstam, Joar AU - Franck, Johan AU - Jayaram-Lindström, Nitya AU - Melas, Philippe A. TI - Genetic liability for anxiety associates with treatment response to the monoamine stabilizer OSU6162 in alcohol dependence AID - 10.1101/2024.03.11.24304098 DP - 2024 Jan 01 TA - medRxiv PG - 2024.03.11.24304098 4099 - http://medrxiv.org/content/early/2024/03/15/2024.03.11.24304098.short 4100 - http://medrxiv.org/content/early/2024/03/15/2024.03.11.24304098.full AB - OSU6162, a monoamine stabilizer, has demonstrated efficacy in reducing alcohol and anxiety-related behaviors in preclinical settings. In a previous randomized, double-blind, placebo-controlled trial involving patients with alcohol dependence (AD), we found that OSU6162 significantly reduced craving for alcohol, but did not alter drinking behaviors. In the present study, we explored the hypothesis that genetic predispositions related to AD or associated traits, might influence the response to OSU6162 treatment in original trial participants (N=56). To investigate this, we calculated polygenic risk scores (PRSs) over several statistical significance thresholds from genome-wide association studies on (i) alcohol use disorder and alcohol consumption (N=200-202k), (ii) problematic alcohol use (N=435k), (iii) drinks per week (N=666k), (iv) major depression (N=500k), and (v) anxiety (using both case-control comparisons and quantitative anxiety factor scores, N=17-18k). Linear regression analyses assessing the interaction effects between PRSs and treatment type (OSU6162 or placebo) identified significant associations when considering anxiety factor scores (FDR<0.05). Specifically, in OSU6162-treated AD individuals, there was a negative correlation between anxiety factor PRS (at the genome-wide significance threshold that included one genetic variant) and several drinking outcomes, including number of drinks consumed, percentage of heavy drinking days, and changes in blood phosphatidylethanol (PEth) levels. These correlations were absent in the placebo group. While preliminary, these findings suggest the potential utility of anxiety PRS in predicting response to OSU6162 treatment in AD. Further research using larger cohorts and more comprehensive genetic data is necessary to confirm these results and to advance personalized medicine approaches in alcohol use disorder.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Royal Physiographic Society in Lund (42797, 2022; P.A.M.), the Ake Wiberg Foundation (M22-0059, 2022; P.A.M.), the Magnus Bergvall Foundation (2022-038, 2022; P.A.M.), the Sigurd and Elsa Golje Memorial Foundation (LA2022-0139; P.A.M.), and the Karolinska Institutet Research Grants (2022-01667, 2022; PAM).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of the regional ethical review board in Stockholm and the Swedish Medical Products Agency gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors